Harrow Health Inc (HROW) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Harrow Health Inc stock (HROW) is currently trading at $36.35. Harrow Health Inc PS ratio (Price-to-Sales) is 4.97. Analyst consensus price target for HROW is $70.62. WallStSmart rates HROW as Sell.
- HROW PE ratio analysis and historical PE chart
- HROW PS ratio (Price-to-Sales) history and trend
- HROW intrinsic value — DCF, Graham Number, EPV models
- HROW stock price prediction 2025 2026 2027 2028 2029 2030
- HROW fair value vs current price
- HROW insider transactions and insider buying
- Is HROW undervalued or overvalued?
- Harrow Health Inc financial analysis — revenue, earnings, cash flow
- HROW Piotroski F-Score and Altman Z-Score
- HROW analyst price target and Smart Rating
Harrow Health Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Harrow Health Inc (HROW) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
Harrow Health Inc (HROW) Key Strengths (4)
Revenue surging 45.40% year-over-year
Strong operational efficiency: $21 kept per $100 revenue
60.91% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Harrow Health Inc (HROW) Areas to Watch (5)
Company is destroying shareholder value
Earnings declining -64.00%, profits shrinking
Company is losing money with a negative profit margin
Very expensive at 23.7x book value
Premium valuation at 5.0x annual revenue
Supporting Valuation Data
Harrow Health Inc (HROW) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 4 register as strengths (avg 8.3/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Operating Margin, Institutional Own.. Profitability is solid with Operating Margin at 20.60%. Growth metrics are encouraging with Revenue Growth at 45.40%.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including Price/Sales (4.97), Price/Book (23.67) suggest expensive pricing. Growth concerns include EPS Growth at -64.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -9.57%, Profit Margin at -2.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -9.57% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 45.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HROW Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HROW's Price-to-Sales ratio of 4.97x trades at a deep discount to its historical average of 187.77x (35th percentile). The current valuation is 100% below its historical high of 3703.75x set in May 2013, and 112% above its historical low of 2.34x in Jan 2018.
Compare HROW with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Harrow Health Inc (HROW) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Harrow Health Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 250M with 45% growth year-over-year. The company is currently unprofitable, posting a -2.0% profit margin.
Key Findings
Revenue growing at 45% YoY, reaching 250M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 8M in free cash flow and 8M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -2.0% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 64% YoY while revenue grew 45%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Harrow Health Inc maintain 45%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Harrow Health Inc.
Bottom Line
Harrow Health Inc is a high-conviction growth story with revenue accelerating at 45% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -2.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(8 last 3 months)
| Insider | Type | Shares |
|---|---|---|
OPALEYE, MANAGEMENT INC. 10% Owner | Sell | -5,000 |
| Insider | Type | Shares |
|---|---|---|
OPALEYE, MANAGEMENT INC. 10% Owner | Sell | -20,000 |
Data sourced from SEC Form 4 filings
Last updated: 12:59:08 PM
About Harrow Health Inc(HROW)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.